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Activation of G proteins by GIV-GEF is a pivot 
point for insulin resistance and sensitivity
ABSTRACT Insulin resistance (IR) is a metabolic disorder characterized by impaired insulin 
signaling and cellular glucose uptake. The current paradigm for insulin signaling centers upon 
the insulin receptor (InsR) and its substrate IRS1; the latter is believed to be the sole conduit 
for postreceptor signaling. Here we challenge that paradigm and show that GIV/Girdin, a 
guanidine exchange factor (GEF) for the trimeric G protein Gαi, is another major hierarchical 
conduit for the metabolic insulin response. By virtue of its ability to directly bind InsR, IRS1, 
and phosphoinositide 3-kinase, GIV serves as a key hub in the immediate postreceptor level, 
which coordinately enhances the metabolic insulin response and glucose uptake in myotubes 
via its GEF function. Site-directed mutagenesis or phosphoinhibition of GIV-GEF by the fatty 
acid/protein kinase C-theta pathway triggers IR. Insulin sensitizers reverse phosphoinhibition 
of GIV and reinstate insulin sensitivity. We also provide evidence for such reversible regula-
tion of GIV-GEF in skeletal muscles from patients with IR. Thus GIV is an essential upstream 
component that couples InsR to G-protein signaling to enhance the metabolic insulin re-
sponse, and impairment of such coupling triggers IR. We also provide evidence that GIV-GEF 
serves as therapeutic target for exogenous manipulation of physiological insulin response 
and reversal of IR in skeletal muscles.
INTRODUCTION
Insulin resistance (IR) is a metabolic disorder in which adipocytes 
and muscle cells fail to take up and metabolize glucose in response 
to the hormone insulin. Although IR is a hallmark of type 2 diabetes 
mellitus (T2DM), IR alone in the absence of T2DM significantly in-
creases the risk for stroke, heart failure, and atherosclerosis (Carter, 
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RNA; siRNA, small interfering RNA; T2DM, type 2 diabetes mellitus; TZDs, thia-
zolidinediones. 
Abbreviations used: DAG, diacyl glycerol; DAPI, 4′,6-diamidino-2-phenylindole; 
F.E., FRET efficiency; FRET, fluorescence resonance energy transfer; GAP, GTPase-
activating protein; GDR, glucose disposal rate; GEF, guanine nucleotide exchange 
Although multiple etiologic factors contribute to the pathogen-
esis of IR (Saltiel and Kahn, 2001), they all ultimately converge to 
suppress critical components of metabolic insulin signaling. Insulin 
binds its receptors (InsR, IGF1R), triggering receptor autophosphor-
ylation and subsequent tyrosine phosphorylation of insulin receptor 
substrate 1 (IRS1), among others. This leads to the recruitment and 
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whereas depletion of GIV suppresses both. Despite these insights, 
the molecular mechanisms that enable GIV to enhance the meta-
bolic insulin-IRS1 response in physiology or mechanisms that derail 
this pathway in the setting of IR remained unknown. On the basis of 
its ability to cross-talk with all these key mediators of metabolic insu-
lin signaling, we asked whether GIV is a key determinant of insulin 
sensitivity in physiology and whether its phosphoregulation by 
PKCθ triggers IR.
RESULTS
Activation of Gαi by GIV-GEF is required for glucose uptake 
in skeletal muscles
To determine the role of GIV-GEF in IR, we used differentiated L6 rat 
skeletal myotubes. Our rationale for this choice was guided by two 
facts: 1) although both adipocytes and skeletal muscles are sites for 
IR, full-length GIV is expressed more abundantly in skeletal muscles 
than in mature adipocytes (Uhlen et al., 2010); and 2) a recent study 
showed that levels of expression of GIV mRNA in skeletal muscle bi-
opsies from normal subjects tracks with insulin sensitivity, as mea-
sured by a hyperinsulinemic–euglycemic clamp (Hartung et al., 
2013). We found that depletion of GIV in L6 myotubes (by ∼80–85%; 
Figure 1A) reduced the efficiency of glucose uptake by ∼50% 
(Figure 1B), as determined by a well-established fluorometric assay 
(Yamamoto et al., 2006). This defect was rescued by stably express-
ing small interfering RNA (siRNA)-resistant wild-type GIV (GIV-WT) 
but not the GEF-deficient F1685A mutant of GIV (GIV-FA), which can 
neither bind nor activate Gαi (Garcia-Marcos et al., 2009; Figure 1, C 
and D). It is noteworthy that the levels of stable expression of GIV-WT 
or mutants in GIV-depleted L6 myotubes were similar to the levels of 
endogenous GIV in these cells (Figure 1C), indicating that the effects 
observed are not merely due to overexpression of GIV at nonphysi-
ological levels. These findings indicate that GIV is required for glu-
cose uptake in skeletal muscles and that its GEF domain is essential.
Next we asked whether phosphoinhibition of GIV’s GEF at 
Ser-1689 by PKCθ (Lopez-Sanchez et al., 2013) also inhibits glucose 
uptake. We found that glucose uptake in cells expressing the consti-
tutively phosphoinhibited S1689D mutant of GIV (GIV-SD) was half 
as efficient compared with those expressing GIV-WT (Figure 1, C 
and D), indicating that phosphoinhibition of GIV’s GEF function by 
PKCθ impairs glucose uptake in response to insulin. These findings 
were reproduced in HeLa cells (Supplemental Figure S1), indicating 
that the effect of GIV-GEF we observe on glucose uptake may not 
be a restricted only to L6 myotubes but may represent a fundamen-
tal effect on IR.
To further pinpoint the impairment of Gi activation by GIV-GEF 
as the cause, we monitored glucose uptake in L6 myotubes stably 
expressing either wild-type (Gαi3-WT) or a dominant-negative 
W258F mutant of Gαi3, henceforth referred to as Gαi3-WF (Figure 1E), 
which cannot bind or be activated by GIV but localizes and interacts 
with Gβγ, G protein–coupled receptors (GPCRs), and Gαi regulators 
similar to Gαi3-WT (Garcia-Marcos et al., 2010). We analyzed Gαi3 
(and not Gαi1/2), because it is the most abundant Gαi subunit ex-
pressed in skeletal muscles, as confirmed by proteomics (Hwang 
et al., 2010). Glucose uptake was reduced in cells expressing 
Gαi3-WF compared with those expressing Gαi3-WT (Figure 1F), 
confirming that GIV drives efficient glucose transport after insulin 
stimulation via its ability to activate Gαi proteins.
GIV binds ligand-activated InsRβ and modulates multiple 
tiers of metabolic insulin signaling via its GEF function
To determine how GIV’s GEF function affects the insulin signaling 
cascade, we analyzed key components of metabolic insulin signaling 
activation of Src homology 2 (SH2) proteins such as p85α (PI3-kinase) 
and downstream activation of Akt (Taniguchi et al., 2006). Akt trig-
gers the translocation of the 12-transmembrane glucose transporter 
4 (GLUT4) to the plasma membrane (PM) by phosphoinhibiting the 
Rab GTPase-activating protein (GAP) AS160 (Miinea et al., 2005). 
Among the many adaptors that relay signals within the insulin cas-
cade, IRS1 is widely believed to serve as the major node for orches-
trating metabolic insulin signaling (Taniguchi et al., 2006).
Besides IRS1, metabolic insulin signaling also relies on the activa-
tion of heterotrimeric G proteins, another major hub in eukaryotic 
signal transduction. InsRs are functionally coupled to the pertussis 
toxin–sensitive Gαi/o proteins, for example, insulin can trigger their 
activation (Rothenberg and Kahn, 1988; Ciaraldi and Maisel, 1989), 
localization (Gohla et al., 2007), and phosphorylation (O’Brien et al., 
1987; Krupinski et al., 1988). Activation of Gi augments insulin sen-
sitivity (Chen et al., 1997; Song et al., 2001), enhances tyrosine 
phosphorylation of both InsR and IRS1 (Moxham and Malbon, 
1996), and triggers efficient translocation of GLUT4 storage vesicles 
(GSVs) to the PM (Ciaraldi and Maisel, 1989; Kanoh et al., 2000; 
Song et al., 2001). Although multiple clues consistently point to a 
critical role of Gi activation in the insulin response, what couples and 
activates Gi downstream of InsR and how such activation may cross-
talk with IRS1-dependent insulin signaling and trigger downstream 
metabolic events remain unknown. Additionally, little is known 
about how G-protein pathways are altered in IR.
With regard to the pathogenesis of IR, suppression of metabolic 
insulin signaling via the IRS1/PI3K pathway is an invariable hallmark 
(Kahn and Flier, 2000; Pessin and Saltiel, 2000; Le Roith and Zick, 
2001). Such suppression occurs via common mechanisms that in-
volve cellular accumulation of lipid metabolites (acyl-CoAs, cerami-
des, diacyglycerol, etc), which activate, among many other kinases, 
the critical protein kinase C-theta (PKCθ; Griffin et al., 1999; Yu 
et al., 2002). PKCθ-dependent phosphoinhibition of IRS1 at Ser1-
101 (Li et al., 2004) is considered an important event that triggers 
lipid-induced IR. PKCθ expression levels are increased in the skeletal 
muscles of obese diabetics and hold an inverse relationship to insu-
lin sensitivity (Schmitz-Peiffer et al., 1997; Yu et al., 2002), and 
PKCθ−/− null mice demonstrate a protective effect against IR despite 
a high-fat diet (Kim et al., 2004). These studies and many others 
have shaped the paradigm that IR is triggered when IRS1 is phos-
phoinhibited by kinases like PKCθ. However, some recent studies 
have revealed inconsistencies in this paradigm (summarized in 
Hoehn et al., 2008). Emerging evidence indicates that IRS1 is insuf-
ficient for orchestrating the insulin response (Krook et al., 1996) and 
that multiple receptor tyrosine kinases (RTKs) can trigger IR inde-
pendent of IRS1 (Hoehn et al., 2008). These studies raise the possi-
bility that major unidentified signaling nodes exist within the insulin 
signaling cascade, whose inhibition via the fatty acid/PKCθ pathway 
triggers IR.
In this study, we define a single, multimodular signal transducer, 
GIV, as a critical node in metabolic insulin signaling. GIV is a guanine 
nucleotide exchange factor (GEF) that activates Gαi1/2/3 (Garcia-
Marcos et al., 2009); contains a SH2-like domain that directly binds 
InsR (Lin et al., 2014); is a direct substrate of InsR, which phosphory-
lates GIV at Y1764 (Lin et al., 2011); is a bona fide enhancer of the 
PI3K-Akt pathway downstream of InsR and other RTKs (Lin et al., 
2011); and is a substrate for PKCθ. The latter phosphorylates and 
inhibits signaling via the GIV-Gαi axis (Lopez-Sanchez et al., 2013). 
Furthermore, a recent study has indicated that GIV may serve as a 
major regulator of the metabolic insulin response in skeletal muscle 
(Hartung et al., 2013); overexpression of GIV in myoblasts leads to 
hyperphosphorylation of IRS1 and enhanced glucose uptake, 
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inhibitory phosphorylation of GIV at S1689 by PKCθ peaked at 
30 min. The time line of these events is consistent with the previously 
described role of this phospho event in the termination of GIV’s GEF 
activity and disengaging GIV from Gαi (Lopez-Sanchez et al., 2013). 
A similar analysis comparing L6 myotubes expressing GIV-WT or 
GIV-SD revealed that phosphoinhibition of GIV’s GEF activity by 
PKCθ affects several of these key upstream events. Compared with 
in L6 myotubes responding to insulin. Immunoblotting (IB) for phos-
phoproteins revealed that insulin triggers activation of GIV at 5 min, 
coincides with peak autophosphorylation of InsRβ, and is followed 
by sustained phosphoactivation of IRS1 and Akt and phosphoinhibi-
tion of the GSV-associated Rab-GAP AS160 (Figure 2A); the latter is 
a key trigger step for exocytosis of GSVs (Miinea et al., 2005). Activa-
tion of PKCθ was initiated by 5 min and sustained up to 30 min, and 
FIGURE 1: Activation of Gαi by GIV-GEF is essential for glucose uptake in skeletal muscles. (A) Left, lysates of L6 
myotubes treated either with control (Scr) or with GIV siRNA were analyzed for GIV and tubulin by IB. Right, bar graph 
displays efficiency of GIV depletion. (B) Control (Scr siRNA) and GIV-depleted (GIV siRNA) L6 myotubes were analyzed 
for glucose uptake after insulin stimulation by fluorometric assay. Bar graphs display fold change in uptake compared 
with starved controls (y-axis). Error bars represent mean ± SD; n = 3. (C) Control L6 myotubes or those stably expressing 
siRNA-resistant GIV-WT, GIV-FA, or GIV-SD were treated (+) or not (−) with either control (Scr) or GIV siRNA before lysis. 
Equal aliquots of whole-cell lysates were analyzed for GIV-FLAG expression by IB for GIV and tubulin. (D) L6 myotubes 
stably expressing siRNA-resistant GIV-WT, GIV-FA, or GIV-SD were depleted of endogenous GIV by siRNA as in C and 
analyzed for glucose uptake after insulin stimulation by fluorometric assay. Bar graphs display fold change in uptake 
compared with starved controls (y-axis). Error bars represent mean ± SD; n = 3. (E and F) L6 myotubes stably expressing 
Gαi3-WT and Gαi3-WF were analyzed for Gαi3 and tubulin by IB (E) and for glucose uptake (F). Bar graphs display fold 
change in uptake compared with starved controls (y-axis). Error bars represent mean ± SD; n = 3.
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FIGURE 2: GIV-GEF binds and enhances autophosphorylation of InsRβ and downstream metabolic insulin response. 
(A) Lysates of serum-starved L6 myotubes stimulated with insulin were analyzed for various components of metabolic 
insulin signaling by IB. (B) Lysates of serum-starved or insulin-stimulated L6 myotubes stably expressing GIV-WT or 
GIV-SD were analyzed for activation of GIV, IRS1, InsRβ, and Akt by IB. (C) Immunoprecipitation was carried out on 
lysates (right) of insulin-treated L6 myotubes with anti-pInsRβ or control immunoglobulin G (IgG). Bound immune 
complexes (left) were analyzed for activated GIV, IRS1, and InsRβ by IB. (D and E) Serum-starved Cos7 cells were 
stimulated with insulin, fixed, and subsequently stained for active GIV (pY1764-GIV; red, D), active IRS1 (pY632-IRS1; 
red, E), active InsRβ (pY1150/51-InsRβ; green), and 4′,6-diamidino-2-phenylindole (DAPI)/DNA (blue). Scale bar: 10 μm. 
(F) Serum-starved control (Scr shRNA) or GIV-depleted (GIV shRNA) Cos7 cells were stimulated with insulin, fixed, and 
stained for active InsRβ (pY1150/51-InsRβ; green) and Gαi3 (red) and analyzed by dSTORM microscopy. A high degree 
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increase in FRET efficiency at/near the PM (F.E. 0.34 ± 0.08) within 5 
min after insulin stimulation; however, in cells expressing GIV-SD, 
that response was blunted (F.E. 0.06 ± 0.03; Figure 3, B and C, and 
Supplemental Figure S3A), confirming that phosphoinhibition of 
GIV-GEF impairs functional phosphorylation of IRS1 at the PM. Be-
cause functional phosphorylation of IRS1 involves several steps, we 
asked whether GIV is required for the two earliest ones, that is, 
translocation of IRS1 from cytosol to the PM and its subsequent 
phosphorylation at that location in response to insulin. Compared 
with control cells, both steps were impaired in GIV-depleted cells 
(Figure 3, D and E, and Supplemental Figure S3, B and C). Coim-
munoprecipitation studies on control or GIV-depleted cells further 
confirmed that recruitment of IRS1 to the activated InsRβ was im-
paired in the absence of GIV (Figure 3F). To further pinpoint whether 
GIV’s GEF function is essential for the recruitment of IRS1 to ligand-
activated InsR, we first looked for insulin-triggered translocation of 
IRS1 from the cytosol to the PM in Cos7 cells expressing WT or SD 
GIV mutant (Supplemental Figure S3D). We found that IRS1 local-
ized to the PM in cells expressing GIV-WT exclusively after ligand 
stimulation, whereas localization at the PM was suppressed in cells 
expressing GIV-SD. Next we analyzed receptor-bound complexes 
by immunoprecipitation assays in GIV-depleted HeLa cells stably 
expressing WT or SD GIV mutant (Figure 3G). In HeLa-GIV-WT cells, 
ligand stimulation triggered robust autophosphorylation of InsR 
(pY1150, 1151), which coincided with the recruitment of pYIRS1, 
GIV, and Gαi3 (Figure 3G). Consistent with our prior observations in 
L6-GIV-SD cells (Figure 2B), autophosphorylation of InsR was sup-
pressed also in HeLa-GIV-SD cells, and receptor-bound complexes 
(InsR-GIV-G protein or InsR-IRS1) were decreased. These results not 
only confirm the role of GIV’s GEF function in enhancing the recruit-
ment of IRS1 to ligand-activated InsR but also demonstrate the in-
hibitory effect of pS1689 GIV on both InsR-IRS1 and InsR-Gαi3 
complexes.
Because of the global effect of GIV depletion we observed on 
IRS1 localization, recruitment, and phosphoactivation, we next 
asked whether GIV binds IRS1. GIV coimmunoprecipitated with 
IRS1 before and after insulin stimulation (Figure 4A), indicating 
that the GIV-IRS1 interaction is constitutive. Pull-down assays with 
recombinant proteins showed that His-GIV-CT specifically bound 
the N-terminus of IRS1, demonstrating that the interaction is di-
rect (Figure 4B). Furthermore, both WT and SD mutant GIV pro-
teins bound IRS1 equally (Supplemental Figure S4, A and B), indi-
cating that phosphorylation of GIV at S1689 by PKCθ does not 
impair GIV’s ability to bind IRS1 and suggesting that GIV may 
bind IRS1 via a domain that is distinct from its GEF module. De-
spite the fact that GIV-SD retains its ability to bind IRS1, localiza-
tion and activation of IRS1 were impaired in GIV-SD cells (Figure 
3, B and C, and Supplemental Figure S3D), suggesting that the 
GIV-IRS1 interaction may serve a different role independent of the 
observed effects of phosphoinhibition of GIV-GEF on IRS1 signal-
ing. We propose that the GIV-IRS1 interaction may serve as a scaf-
fold for the stabilization of InsRβ(RTK)/GIV/IRS1 ternary com-
plexes at the PM, within which GIV’s GEF function may modulate 
the phosphoactivation of IRS1 downstream of growth factors 
(Figure 4C).
L6-GIV-WT cell lines, global suppression of the insulin response was 
encountered in L6-GIV-SD cells, starting with the most upstream 
event, that is, suppressed autophosphorylation of InsRβ at Y1150 
and Y1151, which are essential for maximal phosphoactivation of 
substrate proteins (Flores-Riveros et al., 1989; Figure 2B). At the im-
mediate postreceptor level, phosphoactivation of GIV and IRS1 was 
suppressed, and Akt phosphorylation downstream was impaired 
(Figure 2B). Similar findings were noted also in paired HeLa-GIV-WT 
versus HeLa-GIV-SD cells (Supplemental Figure S2A).
Previous work showed that GIV’s C-terminal SH2-like domain 
directly binds autophosphorylated cytoplasmic tails of multiple 
RTKs, including InsRβ (Lin et al., 2014; Midde et al., 2015). In L6 
myotubes, active GIV[pY1764] coimmunoprecipitated with ligand-
activated InsRβ-IRS1 complexes (Figure 2C). Active GIV[pY1764] 
also colocalized with the autophosphorylated InsRβ at PM micro-
domains (Figure 2D), where activated IRS1 adaptors coexist 
(Figure 2E). These findings suggest that the InsRβ-GIV-IRS1 com-
plexes we observe in Figure 2C are likely assembled at the PM. To 
determine whether GIV links Gαi proteins to ligand-activated InsRβ 
at these PM microdomains, we used direct stochastic optical re-
construction microscopy (dSTORM). This mode of imaging achieves 
a spatial resolution of ∼25 nm, and a high degree of colocalization 
between endogenous proteins indicates they are likely to interact 
(Huang et al., 2010). In control cells, but not in GIV-depleted cells, 
Gαi3 and ligand-activated InsRβ showed a high degree of colocal-
ization along the PM (Figure 2F, yellow pixels), indicating that ac-
tive InsRβ and Gαi3 come within proximity to each other exclu-
sively in the presence of GIV-GEF. As expected, the impairment of 
autophosphorylation of InsRβ in GEF-deficient L6-GIV-SD mutant 
cells was also accompanied by defects in downstream activation of 
Akt and phosphoinactivation of its target Rab-GAP, AS160 (Figure 
2G and Supplemental Figure S2B). Taken together, these results 
demonstrate that GIV binds to ligand-activated InsRβ-IRS1 com-
plexes on microdomains at the PM and links Gαi to such com-
plexes. The presence or absence of a functional GIV-GEF, via which 
GIV links and activates Gi in the vicinity of RTKs, appears to be a 
key determinant of whether multiple tiers within the metabolic in-
sulin signaling cascade are activated maximally, beginning with the 
autophosphorylation and activation of InsRβ (Figure 2H).
GIV directly binds and modulates the localization 
and functional phosphorylation of IRS1
Next we investigated how GIV may affect the phosphorylation/acti-
vation of IRS1, which is a major adaptor for the metabolic insulin 
responses. Because the hypophosphorylation of IRS1 observed by 
immunoblotting lysates of L6 myotubes and HeLa cells expressing 
the GEF-deficient SD phosphomimetic mutant does not provide 
enough information about the spatial and temporal dynamics of 
IRS1 phospho-dephosphorylation in cells, we used a genetically en-
coded fluorescent biosensor, phocus-2nes (Sato et al., 2002) in fluo-
rescence resonance energy transfer (FRET) studies. This biosensor 
shows energy transfer only when Y941 on IRS1 is phosphorylated 
and presents a docking site for the N-SH2 domain of p85α (PI3K), 
thereby providing a readout of the function of such phosphorylation 
(Figure 3A). In cells expressing GIV-WT, we observed a significant 
of colocalization was observed, as determined by the presence of yellow pixels in the merged images. (G) Lysates of 
starved and insulin-stimulated L6 myotubes stably expressing GIV-WT or GIV-SD were analyzed for activation of IRS1, 
AS160, Akt, and tubulin by IB. (H) Schematic illustrating how the presence or absence of a functional GIV-GEF, via which 
GIV links and activates Gi in the vicinity of InsRβ, dictates the intensity of metabolic insulin signaling, beginning with the 
activation and autophosphorylation of InsRβ.
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FIGURE 3: GIV-GEF directly binds and regulates the localization and activation of IRS1. (A) Schematic for the 
biosensor phocus-2nes is shown. Energy transfer from CFP to YFP occurs only when Y941 is phosphorylated and the 
N-SH2 domain of p85α binds the phosphotyrosine ligand. (B and C) Serum-starved Cos7 cells coexpressing phocus-
2nes with either GIV-WT-FLAG or GIV-SD-FLAG were stimulated with insulin, fixed, stained for FLAG (far red), and 
analyzed for FRET using confocal microscopy. Images panels display (from left to right, B) CFP, YFP, FLAG (GIV), and 
intensities of acceptor emission due to FRET in each pixel 5 min after insulin stimulation. Image panels of serum-starved 
(0 min) cells are shown in Supplemental Figure S3A. Bar graph (C) displays the FRET efficiency observed in GIV-WT 
versus GIV-SD cells at 0 and 5 min. The analysis represents five regions of interest from 4 to 6 cells/experiment (three 
independent experiments). Error bars = mean ± SD. (D) Serum-starved control (sh Control) or GIV-depleted (sh GIV) 
Cos7 cells expressing IRS1-HA were stimulated with insulin, fixed, stained for HA (green) and DAPI/DNA (blue), and 
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PA induces phosphoinhibition of GIV-GEF and concomitantly sup-
presses tyrosine-based signaling via GIV. PA requires PKCθ to exert 
such phosphoinhibition, because inhibition of PKCθ abolished 
phosphoinhibition of GIV-GEF (Figure 5B). When PA-treated, insu-
lin-resistant L6 cells were incubated with pioglitazone (Pio), an insu-
lin sensitizer in the thiazolidinedione (TZD) class of drugs, phosphor-
ylation of GIV at S1689 was reduced, and tyrosine phosphorylation 
of GIV was enhanced, indicating that Pio antagonized both the ef-
fects of PA and effectively reversed the phosphoinhibition of GIV-
GEF by PKCθ (Figure 5A). Consistent with its role as a true insulin 
GIV-GEF is a target for the antagonist actions of fatty acids 
and insulin sensitizers
Because PKCθ is the kinase that orchestrates lipid-induced IR 
(Haasch et al., 2006), we next asked whether fatty acids induce IR in 
part by phosphoinhibition of GIV-GEF at S1689 by PKCθ. When we 
induced IR in L6 cells using albumin-conjugated sodium palmitate 
(PA), which is known to activate PKCθ (Griffin et al., 1999), we found 
that phosphorylation of GIV at S1689 was enhanced, GIV’s ability to 
bind Gi was reduced, and phosphorylation of GIV at Y1764 was sup-
pressed (Figure 5A and Supplemental Figure S5A), indicating that 
FIGURE 4: GIV directly and constitutively binds IRS1. (A) Immunoprecipitation was carried out on lysates (right) of 
starved or insulin-treated Cos7 cells expressing IRS1-HA. Lysates and bound immune complexes (left) were analyzed for 
activated GIV (pY1764-GIV), total (t)GIV, IRS1 (HA), p85α, SHP2, and Grb2 by IB. (B) Pull-down assays were carried out 
with recombinant His-GIV-CT and GST-tagged domains of IRS1 (see the Supplemental Material) immobilized on 
glutathione beads. Bound (top) and input (bottom) proteins were analyzed for His-GIV-CT by IB with His mAb. 
(C) Schematic summarizing how the presence or absence of GIV affects localization and phosphoactivation of IRS1.
analyzed by confocal microscopy. Insets show the magnification of the boxed regions. Scale bar: 10 μm. Arrowheads 
denote PM. (E) Serum-starved control (sh Control) or GIV-depleted (sh GIV) Cos7 cells were stimulated with insulin, 
fixed, stained for endogenous pY632-IRS1 (red) and DAPI/DNA (blue), and analyzed by confocal microscopy. Insets 
show the magnification of the boxed regions. Scale bar: 10 μm. (F) Immunoprecipitation was carried out on lysates of 
starved or insulin-stimulated control (sh Control) or GIV-depleted (sh GIV) Cos7 cells expressing InsRβ-FLAG. Bound 
immune complexes were analyzed for IRS1, InsRβ (FLAG), and IgG by IB. IRS1 coimmunoprecipitated with InsRβ in 
control cells but not in GIV-depleted cells. (G) GIV-depleted HeLa cells stably expressing GIV-WT or GIV-SD were 
transiently transfected with InsR-HA, starved, and stimulated with 100 nM insulin for 5 min before lysis. InsR and 
receptor-bound complexes were immunoprecipitated by incubating equal aliquots of lysates with anti-HA mAb or 
contro IgG, followed by protein G beads. Immune complexes were analyzed for GIV, InsR (HA), ligand-activated InsR 
(pY1150, 1151 InsR), pY632 IRS1, and Gαi3 by IB. Equal loading of lysates was confirmed by analyzing GIV, Gαi3, and 
tubulin by IB. Maximal autophosphorylation of InsR and recruitment of GIV, IRS1, and Gαi3 to the receptor was 
observed in cells expressing GIV-WT exclusively after insulin stimulation, but not in cells expressing GIV-SD.
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FIGURE 5: Phosphoinhibition of GIV-GEF by PKCθ is required for PA-induced IR and dephosphorylation of GIV-GEF is 
essential for the action of Pio. (A) Lysates of L6 myotubes treated (+) or not (−) with PA alone or a combination of PA 
and Pio were analyzed for phosphorylation of GIV at S1689 and Y1764 and total (t)GIV by IB. (B) Lysates of L6 myotubes 
treated (+) or not (−) with PA alone or a combination of PA and a pseudosubstrate PKCθ inhibitor were analyzed for 
phosphorylation of GIV at S1689 (pS1689 GIV), total (t)GIV, and tubulin by IB. (C) L6 myotubes stably expressing 
siRNA-resistant GIV-WT or GIV-SA were depleted of endogenous GIV by siRNA, treated with PA (+) or vehicle control 
(−), and subsequently analyzed for insulin-stimulated glucose uptake by fluorometric assay. Bar graph displays fold 
change in glucose uptake compared with starved controls (y-axis). Error bars represent mean ± SD; n = 3. (D) L6 
myotubes stably expressing siRNA-resistant GIV-WT or GIV-SD were depleted of endogenous GIV by siRNA, treated (+) 
or not (−) with Pio, and subsequently stimulated with insulin before lysis. Lysates were analyzed for activation of GIV 
(pY1764 GIV) and Akt (pS473Akt) by IB. (E) L6 myotubes stably expressing siRNA-resistant GIV-WT or GIV-SD were 
depleted of endogenous GIV by siRNA, treated (+) or not (−) with Pio, and subsequently analyzed for insulin-stimulated 
glucose uptake by fluorometric assay. Bar graph displays fold change compared with starved controls (y-axis). Error bars 
represent mean ± SD; n = 3. (F) Equal aliquots of lysates of vastus lateralis muscle biopsies from obese T2DM subjects, 
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therefore abolishes activation of Gi by GIV, is a common pivot point 
for both PA and Pio to exert their antagonistic actions in IR. Phos-
phorylation at S1689 is essential for PA to induce IR, whereas de-
phosphorylation is required for Pio to enhance tyrosine phosphory-
lation of IRS1 and GIV, restore Akt signaling, and reinstate insulin 
sensitivity (Figure 5I).
Cell-permeant GIV-derived peptides can effectively reverse 
IR in skeletal muscle
We next asked whether GIV-GEF can serve as a therapeutic target 
for exogenous modulation of IR. To investigate this, we used re-
cently validated recombinant, cell-permeant TAT-tagged GIV-CT 
peptides (WT and GEF-deficient FA mutant peptides spanning GIV’s 
GEF and SH2-like domains; Figure 6, A and B). These peptides offer 
a nongenetic approach for exogenous manipulation of GIV-GEF–
dependent signaling programs and cellular phenotypes in diverse 
cells and a variety of pathophysiological processes (Ma et al., 2015). 
L6 myotubes homogeneously took up TAT peptides (∼90% effi-
ciency of uptake; Figure 6C). Uptake of GIV-CT-WT peptides was 
associated with enhancement of stress-fiber formation and phos-
phorylation of IRS1 and Akt proteins in response to insulin (Figure 6, 
C and D). However, uptake of GIV-CT-FA peptides disrupted the 
actin stress fibers, as shown previously in other cell lines, and sup-
pressed IRS1 and Akt phosphorylation in response to insulin. Con-
sistent with these signaling programs, insulin-stimulated glucose 
uptake in the basal state was unaffected by GIV-CT-WT peptides but 
was significantly inhibited by GIV-CT-FA peptides (Figure 6E). GIV-
CT-WT, but not the FA mutant peptides, effectively reversed PA-in-
duced IR (Figure 6F), and ∼800 nM of WT peptide was as effective 
as 50 μM Pio in reversing such IR (Figure 6G). These studies demon-
strate that cell-permeant GIV-CT peptides can enhance metabolic 
insulin signaling and reverse IR effectively in a GEF-dependent way.
DISCUSSION
Phosphoinhibition of GIV-GEF by PKCθ triggers lipid-
induced IR; dephosphorylation of GIV-GEF reinstates 
insulin sensitivity
The fundamental discovery in this work is that GIV-GEF plays a ma-
jor role as a dominant conduit for insulin response in the skeletal 
muscle, and identification of key phospho events that allow this GEF 
to serve as a decisive pivot/node for cellular insulin response in 
physiology and disease (see Figure 7). In lean individuals, insulin 
triggers activation of GIV by tyrosine phosphorylation (pY), GIV’s 
GEF function is turned “on,” and Gαi is activated, metabolic insulin 
signaling is initiated through the InsR/IRS1/PI3K/Akt signaling axis, 
culminating in efficient exocytosis of GSVs and subsequent uptake 
of glucose. In the obese, circulating free fatty acids trigger the ac-
cumulation of diacyl glycerol (DAG) and activation of PKCθ in skel-
etal muscle, which in turn phosphorylates GIV’s GEF motif at S1689 
sensitizer that improves insulin action in peripheral tissues, Pio also 
enhanced tyrosine phosphorylation of GIV and Akt signaling trig-
gered by insulin in insulin-sensitive L6 cells never exposed to PA 
(Supplemental Figure S5, B and C).
We then investigated whether phosphoinhibition of GIV-GEF by 
PKCθ in L6 myotubes plays a role in mediating the antagonistic ef-
fects of PA and Pio in the induction and reversal of IR, respectively. 
PA induced IR in L6-GIV-WT cells, as determined by a blunted glu-
cose-uptake response to insulin (Figure 5C). However, L6 cells ex-
pressing a nonphosphorylatable GIV S1689A mutant (L6-GIV-SA) 
were resistant to PA, that is, these cells remained sensitive to insulin 
regardless of PA treatment and demonstrated higher glucose up-
take compared with L6-GIV-WT cells (Figure 5C). These results dem-
onstrate that the selective inhibition of GIV-GEF by PKCθ via phos-
phorylation of a single Ser-1689 is an essential mechanism by which 
PA triggers IR in L6 myotubes. As for Pio, we found that it reinstated 
insulin signaling in PA-treated, insulin resistant L6-GIV-WT cells, as 
determined by restored tyrosine phosphorylation of GIV and Akt 
signaling (Figure 5D and Supplemental Figure S5D). However, L6 
cells expressing a constitutively phosphoinhibited GIV SD mutant 
(L6-GIV-SD) were resistant to Pio, that is, these cells showed no dis-
cernible enhancement of signaling compared with L6-GIV-WT cells 
(Figure 5D and Supplemental Figure S5D). Furthermore, Pio re-
versed the PA-induced IR state in L6-GIV-WT cells, but not in L6-GIV-
SD cells, as determined by glucose uptake after insulin stimulation 
(Figure 5E). Because Pio is known to improve insulin sensitivity in 
muscle tissue in part by antagonizing the activity of protein kinases 
such as PKCθ (Markova et al., 2010), our results demonstrate that 
reversal of phosphoinhibition of GIV-GEF by PKCθ on Ser-1689 is an 
essential mechanism via which Pio reverses IR and sensitizes L6 
myotubes to the action of insulin. The inability to reverse such phos-
phoinhibition (as in the case of the GIV-SD mutant, which mimics a 
constitutive phosphoinhibited state) makes cells nonresponsive to 
the insulin-sensitizing actions of Pio.
The physiological significance of these observations in cultured 
L6 myotubes was confirmed by findings in patients with IR, in whom 
chronic treatment with Pio reduced the phosphoinhibition of GIV-
GEF and enhanced phosphorylation of Akt in skeletal muscles (vas-
tus lateralis) of obese T2DM patients (Figure 5F). Moreover, patients 
with polycystic ovarian syndrome (PCOS) in whom IR was clinically 
reversed by Pio therapy, that is, responders (as determined by 24-h 
glucose levels and glucose disposal rate [GDR] determined by a 
hyperinsulinemic–euglycemic clamp) showed a significant reduction 
in phosphoinhibition of GIV at S1689 in their muscles. By contrast, 
PCOS patients who failed the Pio treatment trial (i.e., nonresponders) 
had high pretreatment and/or posttreatment levels of phosphoinhi-
bition of GIV-GEF (Figure 5, G and H). Taken together, our results 
demonstrate that a single phospho event (PKCθ-dependent phos-
phorylation of GIV at S1689), which selectively inhibits GIV-GEF and 
obtained before (basal) or after 6 mo of Pio therapy, were analyzed for phosphoinhibition of GIV-GEF (pS1689 GIV) and 
phospho Akt (pS473 Akt) by IB. Representative samples are shown (n = 8). (G and H) Equal aliquots of lysates of vastus 
lateralis muscle biopsies from patients with PCOS, obtained before (basal) and after Pio therapy, were analyzed for 
pS1689GIV by IB. (G) A representative immunoblot of biopsies obtained from “responder” and “nonresponder” 
patients are shown (n = 8). Bar graph displays fold change in GIV phosphorylation at S1689 observed in normal and 
PCOS patients before and after Pio treatment (y-axis) (H). B, basal; Pio, pioglitazone treatment. Error bars represent 
mean ± SD. (I) Schematic illustrates our proposed model for GIV’s role as a pivot for the antagonistic actions of fatty 
acids like palmitate that trigger IR (red arrow) and insulin sensitizers like Pio that reverse IR (green). Phosphorylation at 
S1689 is essential for PA to induce IR, whereas dephosphorylation is required for Pio to enhance tyrosine 
phosphorylation of IRS1 and GIV, restore Akt signaling, and reinstate insulin sensitivity.
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FIGURE 6: Cell-permeant TAT-GIV-CT-WT peptides, but not FA mutant peptides, effectively reverse lipid-induced IR in 
skeletal muscles. (A) Design of the cell-permeant TAT-GIV-CT peptides is shown. TAT-PTD was fused to His and HA tags 
and coupled via a linker (GGSGHSG) to the C-terminus of GIV (aa 1660–1870). (B) Purified recombinant TAT-GIV-CT 
peptides were analyzed by Coomassie blue staining and by IB with anti GIV-CT and anti-His antibodies. (C) L6 myotubes 
were treated with TAT-GIV-CT-WT or FA peptides and cultured overnight in low serum conditions (0.2% fetal bovine 
serum) before fixation. Fixed cells were stained for His (green), phalloidin (F-actin, red), and DAPI/DNA (blue) and 
analyzed by confocal microscopy. (D) L6 myotubes were treated with TAT-GIV-CT-WT or FA peptides, starved, and 
stimulated with insulin before lysis. Equal aliquots of lysates were analyzed for transduction of TAT-peptides with 
anti-His antibody, activation of IRS1 (pY632-IRS1) and Akt (pS473) by IB. (E) L6 myotubes were treated with 
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TAT-GIV-CT-WT or FA peptides, starved, and subsequently analyzed for insulin-stimulated glucose uptake by 
fluorometric assay. Bar graph displays fold change in uptake compared with starved controls (y-axis). Error bars 
represent mean ± SD. (F) L6 myotubes were treated (+) or not (–) with PA to induce IR, then transduced with TAT-GIV-CT-
WT or FA peptides, and subsequently analyzed for insulin-stimulated glucose uptake by fluorometric assay. Bar graph 
displays fold change in uptake compared with starved controls (y-axis). Error bars represent mean ± SD. (G) L6 
myotubes were treated (+) or not (–) with PA to induce IR, then either treated with Pio or transduced with TAT-GIV-CT-
WT peptides (as indicated), and subsequently analyzed for insulin-stimulated glucose uptake by fluorometric assay. Bar 
graph displays fold change in uptake compared with starved controls (y-axis). Error bars represent mean ± SD.
FIGURE 7: Schematic summarizing how GIV-GEF is a pivotal node for metabolic insulin response in lean normals (left) 
and for lipid-induced IR in the obese (right). Left, in lean individuals, insulin triggers tyrosine phosphorylation and 
activation of GIV (pY1764), GIV’s GEF function is “on” and Gαi is activated. Metabolic insulin signaling is enhanced 
through the InsR/IRS1/PI3K/Akt/AS160 signaling axis, resulting in efficient exocytosis of GSVs and rapid uptake of 
glucose. Right, in the obese, circulating free fatty acids trigger the accumulation of DAG, and PKCθ is activated. PKCθ 
phosphorylates GIV at S1689 and turns “off” its GEF function. Consequently, Gαi remains inactive, and the InsR/IRS1/
PI3K/Akt/AS160 signaling cascade is suppressed, thereby triggering IR.
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activation of Gαi by GIV’s GEF function can similarly enhance auto-
phosphorylation of yet another RTK, EGFR (Ghosh et al., 2010). In 
both instances, suppression of protein tyrosine phosphatases (PTPs) 
has been implicated as the mechanism for enhanced receptor auto-
phosphorylation (Moxham and Malbon, 1996; Lin et al., 2014). Be-
cause GIV directly binds ligand-activated InsRβ (Lin et al., 2014) and 
triggers the formation of InsRβ-Gαi complexes at the PM, it is pos-
sible that the formation of such InsRβ-GIV-Gαi complexes sup-
presses the recruitment and/or activation of key PTPases. We con-
clude that the GIV-Gαi axis enhances cellular insulin response by 
increasing InsRβ kinase activity and autophosphorylation, two up-
stream events in insulin signaling.
At the immediate postreceptor level, we demonstrate that GIV 
binds and modulates the functions of IRS1. Activation of Gαi by GIV 
enhanced the recruitment of IRS1 to the ligand-activated receptors 
at the PM, triggered robust tyrosine phosphorylation at Y632 and 
Y941 on IRS1, and enhanced the formation of IRS1-p85α(PI3K) 
complexes. Unlike the ligand-dependent nature of InsRβ-GIV or 
InsRβ-IRS1 (Sun et al., 1991) interactions, the GIV-IRS1 interaction 
was constitutive. We also provide evidence that this binding was 
direct and that it involved the C-terminal region of GIV and the N-
terminal region of IRS1. The latter contains a phosphotyrosine-bind-
ing domain (PTB) that is responsible for the direct interaction of IRS1 
with InsRβ (Eck et al., 1996). Our findings of InsRβ-GIV-IRS1 com-
plexes upon insulin stimulation suggest that GIV may bind IRS1 at a 
distinct site where the autophosphorylated cytoplasmic tail of InsRβ 
docks within the PTB. The enhanced recruitment of IRS1 to InsRβ in 
the presence of GIV suggests that GIV may serve as a signal ampli-
fier at the immediate postreceptor level by facilitating the recruit-
ment of more IRS1 adaptors per activated InsR. Based on recent 
experimental evidence that questions the exclusivity of IRS1 for 
InsRβ (Knowlden et al., 2008) and that shows GIV is capable of bind-
ing multiple RTKs (e.g., EGFR, PDGFR, VEGFR; Lin et al., 2014; Lo-
pez-Sanchez et al., 2014), it is possible that GIV provides the neces-
sary molecular basis for IRS1 to serve as a common conduit for 
metabolic response observed downstream of receptors other than 
InsRβ.
Although the precise mechanism of GIV-IRS1 interaction remains 
uncertain, this interaction adds GIV to the lengthy list of proteins 
that IRS1 scaffolds within the insulin signaling cascade (White, 2006). 
The finding that GIV enhanced tyrosine phosphorylation of IRS1 is 
consistent with the concomitant increase in the kinase activity of 
InsRβ and enhanced recruitment of IRS1 to the PM, the latter is a 
prerequisite for maximal tyrosine phosphorylation of IRS1 (Myers 
et al., 1995; Voliovitch et al., 1995). We conclude that GIV is re-
quired for maximal PM recruitment and tyrosine phosphorylation of 
IRS1, both key events implicated in metabolic insulin signaling via 
IRS1. In doing so, and by virtue of its ability to directly bind and 
bring together several other components of the metabolic insulin 
response (InsR, IRS1, G proteins, actin, PI3K, Akt), GIV serves as an 
integral hub at the immediate postreceptor that fine-tunes IRS1-
dependent metabolic insulin signaling.
Further downstream, the PI3K-Akt signaling pathway was maxi-
mally enhanced in the presence of an intact GIV-GEF, and a major 
pathway downstream of Akt was triggered, that is, phosphoinhibi-
tion of the Rab-GAP AS160. Prior studies have demonstrated that 
docking of GSVs at the PM requires activation of Rab proteins 
(Miinea et al., 2005; Sun et al., 2010; Lansey et al., 2012) in re-
sponse to insulin (Bai et al., 2007). By triggering the phosphoinhi-
bition of Rab-GAP AS160, GIV’s GEF function is likely to affect the 
exocytosis of GSVs via potentiation of Rab GTPases. We conclude 
that GIV functionally interacts with and enhances key signaling 
and selectively turns “off” the GEF function. Consequently, Gαi re-
mains inactive, and a majority of the key elements of metabolic in-
sulin signaling are suppressed, thereby triggering IR.
We also provide evidence that reversible phosphorylation of GIV 
at S1689 by PKCθ and the ability of this single phospho event to 
modulate the InsR-GIV-Gαi signaling axis are critical determinants of 
cellular insulin responses. We demonstrated that this phospho event 
alone is sufficient to mimic fatty acid–induced IR and that fatty acids 
require such phosphorylation to induce IR. Although this study dis-
sected the interplay between GIV and PKCθ in lipid-induced IR, be-
cause GIV can intercept signaling downstream of multiple classes of 
receptors (GPCRs and RTKs) and non-RTKs alike (reviewed in Gar-
cia-Marcos et al., 2015) and is an enhancer of STAT3 as well as its 
transcriptional target (Dunkel et al., 2012), it is possible that GIV is a 
central node for other major triggers of IR, that is, inflammation, 
suppression of adiponectin, leptin resistance, and so on, which also 
require activation of PKCθ (Itani et al., 2000; Lin et al., 2000; Shul-
man, 2000; Anderson et al., 2006) and/or the JAK-STAT3 pathway 
(Mashili et al., 2013; Wunderlich et al., 2013).
We also show that TZDs like Pio release the phosphoinhibition 
on GIV-GEF and restore its function. Such restoration was essential 
for TZD action, because TZDs failed to reverse IR and reinstate insu-
lin sensitivity in cells expressing the constitutively phosphomimic 
GIV-S1689D mutant. Because chronic TZD therapy does not sup-
press PKCθ (Markova et al., 2010), the reduction in levels of GIV 
phosphorylation at S1689 we observed after TZD therapy is likely to 
be a consequence of dephosphorylation by one of the many S/T 
phosphatases that are activated by TZDs in a PPARγ-dependent 
manner (Altiok et al., 1997; Pugazhenthi and Khandelwal, 1998; 
Sharma et al., 2004; Cho et al., 2006). Regardless of the mechanism(s) 
involved, our results indicate that GIV is a major target of TZDs that 
can account, in part, for TZD action on skeletal muscle. We conclude 
that reversible phosphorylation at S1689 and inhibition of the GEF 
function, via which GIV activates Gαi, serves as a molecular switch 
for flipping skeletal muscles between insulin-sensitive and insulin-
resistant states. Because GIV specifically binds Gαi and not Gαq/11 
(Le-Niculescu et al., 2005), these findings do not account for the 
previously described role of yet another G protein, Gαq/11, in insu-
lin response (Imamura et al., 1999).
GIV’s GEF function modulates several tiers within the 
metabolic insulin signaling cascade
We demonstrated that activation of Gαi by GIV impacts many tiers 
within the insulin signaling cascade and that phosphoinhibition of 
GIV’s GEF function antagonizes them all. We previously showed that 
GIV directly binds autophosphorylated cytoplasmic tails of ligand-
activated InsR via its C-terminal SH2-like module (Lin et al., 2014). 
Both the SH2-like module and GIV’s GEF functions are critical for 
coupling of G proteins to ligand-activated InsR (Garcia-Marcos 
et al., 2011; Lin et al., 2014; Midde et al., 2015). We show here that, 
at the level of the receptor, activation of Gαi via GIV’s GEF motif is 
required for maximal autophosphorylation and activation of InsRβ 
and recruitment and phosphoactivation of its major substrate, IRS1. 
The sites of autophosphorylation on InsRβ that GIV enhanced, 
Y1150 and Y1151, are required for maximal activation of the InsRβ 
kinase (White et al., 1988), and a failure to activate InsRβ kinase in 
skeletal muscles has been implicated in IR (Maegawa et al., 1991; 
Nolan et al., 1994; Goodyear et al., 1995). Although it is unclear how 
activation of Gαi by GIV may enhance receptor autophosphoryla-
tion, it is not entirely surprising, because activation of Gαi has previ-
ously been implicated in the enhancement of InsR autophosphory-
lation (Kreuzer et al., 2004) and because we previously showed that 
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In conclusion, we have defined activation of Gαi by GIV’s GEF 
function as a central node that coordinately enhances the physiologi-
cal insulin response and how its deregulation heralds IR. Because this 
node also serves as the point of convergence for the antagonistic ac-
tions of fatty acids and insulin sensitizers, selective modulation of this 
node emerges as a promising and precise strategy to treat T2DM and 
other conditions in which IR plays a central pathophysiological role.
MATERIALS AND METHODS
Detailed methods are presented in the Supplemental Materials.
Cell culture, transfection, IB, immunofluorescence, and 
protein–protein interaction assays
These assays were carried out exactly as described before (Ghosh 
et al., 2008, 2010). All Odyssey images were processed using Im-
ageJ software (National Institutes of Health [NIH], Bethesda, MD) 
and were assembled for presentation using Photoshop and Illustra-
tor software (Adobe Systems, San Jose, CA).
dSTORM and FRET imaging
Direct Stochastic Optical Reconstruction Microscopy imaging was 
performed to reveal the interaction endogenous Gαi3 and active 
InsRβ at molecular level (Huang et al., 2010). Control short hairpin 
RNA (shRNA) and GIV shRNA Cos7 stable cells were starved and 
stimulated with 100 nM insulin and stained with anti-Gαi3 (1:30; Cal-
biochem, San Diego, CA) and phosho-InRβ antibodies (1:100; Santa 
Cruz Biotechnologies, Dallas, TX).
FRET assays were performed using the intracellular phosphoryla-
tion biosensors custom (phocus-2nes) designed by Yoshio Umeza-
wa’s group at the University of Tokyo (Sato et al., 2002). GIV shRNA 
Cos7 stable cells were transfected with phocus-2nes and GIV-WT-
FLAG or GIV-S1689D-FLAG. Cells were starved and stimulated with 
insulin and were stained with anti-FLAG antibody following the stan-
dard immunofluorescence protocol.
Patient samples
Biopsies of vastus lateralis muscle used for GIV phosphorylation 
analysis were collected in the Special Diagnostic and Treatment Unit 
of the Veterans Affairs Medical Center (San Diego, CA) and the Gen-
eral Clinical Research Center, University of California, San Diego 
(UCSD). Muscle samples were collected from healthy, normal, cy-
cling women or women with PCOS before and after a course of 
treatment with Pio (45 mg/d, for 6 mo; Aroda et al., 2009). Collec-
tion and storage of muscle samples and measurement of eGDR 
were performed as described previously (Thorburn et al., 1990). The 
experimental protocol was approved by the Human Research Pro-
tection Program of the UCSD.
Data analysis and statistics
All experiments were repeated at least three times, and results 
were presented either as one representative experiment or as 
mean ± SD or SEM. Statistical significance was assessed with the 
two-tailed Student’s t test.
events that can also coordinate membrane trafficking within the 
insulin response cascade, and in doing so, it delineates a molecular 
basis for the observed engagement between these events during 
insulin-triggered glucose uptake into cells (Leto and Saltiel, 2012).
Although this study has specifically dissected the role of GIV’s 
GEF function in coordinating key signaling events that comprise the 
metabolic insulin response, it is notable that the GEF motif merely 
represents a stretch of ∼30–35 aa within a 1871-aa-long, multimodu-
lar protein made up of several other key functional modules that 
may take part in other key aspects of glucose uptake. One such 
well-defined module is GIV’s SH2-like domain, which is necessary 
and sufficient for GIV to directly bind the autophosphorylated cyto-
plasmic tail of InsR; without a functional SH2-like domain, GIV can 
neither bind InsR nor facilitate the formation of InsR–G protein com-
plexes (Lin et al., 2014). Another such module, whose boundaries 
remain to be defined, but which appears to be functionally distinct 
from the GEF module, is a region within GIV’s C-terminus that di-
rectly binds IRS1 (Figure 4B); it is possible that selective inhibition of 
GIV-IRS1 interaction may also impair the metabolic insulin response 
and glucose uptake. Our own recent findings that GIV regulates 
cargo trafficking from the ER-Golgi intermediate compartment 
(ERGIC) to the Golgi (Lo et al., 2015) raises the possibility that GIV 
may also play a role in regulating GLUT4 trafficking from the Golgi 
to GSVs. Additionally, GIV is also known to regulate clathrin-medi-
ated endocytosis and endocytic trafficking (Beas et al., 2012; Weng 
et al., 2014), two processes closely intertwined with and key deter-
minants of the kinetics of GLUT4 trafficking, glucose uptake, and 
down-regulation of insulin receptor signaling. Because the actin cy-
toskeleton has also been described as a tether for GSVs (Stockli 
et al., 2011), it is possible that another previously characterized 
module that enables GIV to remodel the cortical actin cytoskeleton 
further aids in GSV exocytosis and glucose uptake (Enomoto et al., 
2005; Ghosh et al., 2010). Thus, it is likely that many of GIV’s mod-
ules, not just its C-terminal GEF motif, may play a role in integrating 
signaling events with vesicular trafficking and cytoskeletal changes 
to orchestrate glucose uptake after insulin stimulation.
Selective modulation of GIV-GEF emerges as a therapeutic 
strategy for reversal of IR
We found that cell-penetrable GIV peptides were as effective as 
TZDs in their ability to reverse fatty acid–induced IR in a GEF-depen-
dent way, and activation of Gαi via GIV’s GEF thus mimics the action 
and matches the potency of TZDs. Because postprandial lipotoxicity 
can also suppress GIV expression in skeletal muscles (Supplemental 
Figure S6), our results using cell-permeant peptides suggest that 
replenishing GIV-CT (with active GEF) by gene therapy may be a 
viable strategy for the treatment of IR. Other strategies include ago-
nists of GIV’s GEF function, antagonists of the inhibitory phospho 
event on GIV triggered by PKCθ, or activation of phosphatases that 
dephosphorylate GIV—all approaches that may serve as more re-
fined, effective, and precise therapeutic strategies to reverse IR in 
skeletal muscle. GIV expressed in adipocytes is also likely to en-
hance the metabolic insulin response in adipose tissue, the second 
major site of IR. However, phosphoinhibition of GIV-GEF by PKCθ is 
unlikely to be a trigger for IR, because this kinase is undetectable in 
adipocytes (Fleming et al., 1998). Instead, mechanisms such as tran-
scriptional repression, single nucleotide polymorphisms (SNPs), or 
posttranslational modifications (splice variants) that reduce the lev-
els of full-length GIV may play a role. Further studies are required to 
determine how IR is triggered in adipocytes and whether the GIV-
targeted approaches we show here can reverse IR also in the adi-
pose tissue.
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